1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chemgenes Corporation has 1 pending office action currently under review. This action is assigned to 1 distinct examiner, DIAMOND, ALAN D, who is situated within 1 distinct art unit. This structure indicates a highly specific prosecution focus with no current fragmentation across different office departments.
DIAMOND, ALAN D serves as the busiest examiner for the portfolio with 1 pending office action. Because this examiner handles the only active matter, the company's immediate patent strategy depends entirely on the interactions within this single art unit. Practitioners should prepare for a focused dialogue centered on the specific requirements of this individual examiner. The presence of 1 distinct art unit ensures that the technical standards applied to the case remain consistent throughout the current phase of prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18986503 | RNA Synthesis-Phosphoramidites for Synthetic RNA in the Reverse Direction, and Application in Convenient Introduction of Ligands, Chromophores and Modifications of Synthetic RNA at the 3'-End | DIAMOND, ALAN D | 3991 | §112Other | Non-Final OA | — | Pending | Dec 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChemgenes Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alan D Diamond has the most, with 1 of Chemgenes Corporation's pending office actions.
